Last updated date
ABOUT THIS STUDY
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of
Xalatan.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Patient with ocular hypertension at least 22mg Hg
- Patient must be over 18 years old
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- None listed in the protocol
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Glaucoma, Ocular HypertensionNon-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
NCT01012245
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionA Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
NCT00638742
- Artesia, California
- Atlanta, Georgia
- Atlanta, Georgia
- North Dartmouth, Massachusetts
- Minneapolis, Minnesota
- Durham, North Carolina
- Koebenhavn OE,
- Catania,
- Coimbra,
- Lisboa,
- Mayfair West,
- Madrid,
- Madrid,
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionComparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US
NCT00847483
- Belleflower, California
- Inglewood, California
- San Diego, California
- San Diego, California
- San Francisco, California
- Gainesville, Florida
- Lakeland, Florida
- Ormond Beach, Florida
- Atlanta, Georgia
- Bloomingdale, Illinois
- Evansville, Indiana
- Louisville, Kentucky
- Louisville, Kentucky
- Shreveport, Louisiana
- Bangor, Maine
- Kansas City, Missouri
- Kansas City, Missouri
- Omaha, Nebraska
- Las Vegas, Nevada
- Bloomfield, New Jersey
- Willingboro, New Jersey
- Charlotte, North Carolina
- Winston-Salem, North Carolina
- Streetsboro, Ohio
- Oklahoma City, Oklahoma
- Tulsa, Oklahoma
- Pittsburgh, Pennsylvania
- Charleston, South Carolina
- Charleston, South Carolina
- Charleston, South Carolina
- Maryville, Tennessee
- Memphis, Tennessee
- Dallas, Texas
- El Paso, Texas
- Houston, Texas
- Layton, Utah
- Norfolk, Virginia
- Norfolk, Virginia
- Virginia Beach, Virginia
- Wenatchee, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionEfficacy and Tolerability of Xalatan in Patients
NCT00950690
- Alexandria,
- Jeddah,
- Umm Al Quwain,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Efficacy and Tolerability of Xalatan in Patients | |||
| Official Title | Observational Study Assessing The Efficacy And Tolerability Of Xalatan? In Patients With Open Angle Glaucoma And /Or Ocular Hypertension. | |||
| Brief Summary | Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan. | |||
| Detailed Description |
| |||
| Study Type | Observational | |||
| Study Design | Time Perspective: Prospective | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Not Provided | |||
| Sampling Method | Non-Probability Sample | |||
| Study Population | adults with glauocma or ocular hypertension | |||
| Condition |
| |||
| Intervention | Drug: Xalatan 0.005% eye drops
ophthalmic solution dosed once daily for 3 months Other Name: latanoprost | |||
| Study Groups/Cohorts | Study Drug - Xalatan 0.005% eye drops
Intervention: Drug: Xalatan 0.005% eye drops | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 1289 | |||
| Original Actual Enrollment | 1408 | |||
| Actual Study Completion Date | December 2007 | |||
| Actual Primary Completion Date | December 2007 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years to 65 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | No | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Egypt, Saudi Arabia, United Arab Emirates | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT00950690 | |||
| Other Study ID Numbers | A6111128 A6111128 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
| Study Sponsor | Pfizer | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2011 | |||